• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在细胞减灭术+腹腔内化疗中的膈膜干预的长期生存和围手术倾向性评分匹配结果。

Long term survival and perioperative propensity score matched outcomes in diaphragmatic interventions in cytoreductive surgery + intra-peritoneal chemotherapy.

机构信息

Peritonectomy and Liver Unit, St George Hospital, NSW, Australia.

Peritonectomy and Liver Unit, St George Hospital, NSW, Australia; University of New South Wales, Medicine, St George Clinical School, Australia; Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.

出版信息

Eur J Surg Oncol. 2019 Apr;45(4):620-624. doi: 10.1016/j.ejso.2018.12.021. Epub 2018 Dec 29.

DOI:10.1016/j.ejso.2018.12.021
PMID:30611566
Abstract

OBJECTIVES

To assess the impact of short and long term outcomes of diaphragmatic interventions in cyto-reductive surgery (CRS) and intra-peritoneal chemotherapy (IPC).

METHODS

1230 consecutive CRS/IPC procedures were preformed between 1996 and 2018 in Sydney, Australia. Redo procedures and incomplete cyto-reductions were excluded. Among these, 599 underwent diaphragmatic intervention. Preoperative heterogeneity was assessed for in 6 parameters and addressed with propensity score matching. CRS/IPC requiring diaphragmatic interventions were compared to CRS/IPC without diaphragmatic involvement. Ten perioperative outcomes were measured. Overall survival was assessed based on diagnosis type.

RESULTS

Intraoperative results revealed a significant increase in operative hours (7.85 vs. 7.28, p = 0.033). Transfusion requirements were insignificantly different. Postoperatively, increased grade III and IV complications (36% vs. 26%, p = 0.052) were noted. There was no difference with regards to intensive care stay, hospital length of stay, hospital death and return to theatre. In terms of respiratory specific complications, an increased incidence of pneumothorax (13% vs. 3%, p = 0.001) and pleural effusions (24% vs. 16%, p = 0.043) were noted, whilst the differences in pneumonia were insignificant. Overall survival revealed diaphragm interventions; did not affect survival outcomes in colorectal cancers (p = 0.750, RR = 1.077, CI 0.683-1.697) and increased relative risk in low-grade appendiceal mucinous neoplasms (p = 0.025, RR = 2.437, CI 1.121-5.298).

CONCLUSION

After our three-tiered research strategy, we conclude that despite the marginal increase in short term morbidity; diaphragmatic interventions do not decrease survival in colorectal cancers and diaphragmatic disease in LAMNs maybe an independent prognosticator of disease aggression.

摘要

目的

评估细胞减灭术(CRS)和腹腔内化疗(IPC)中膈肌干预的短期和长期结果的影响。

方法

1996 年至 2018 年在澳大利亚悉尼进行了 1230 例连续的 CRS/IPC 手术。排除了重复手术和不完全细胞减灭术。其中 599 例行膈肌干预。评估了 6 个参数的术前异质性,并采用倾向评分匹配进行了处理。CRS/IPC 需膈肌干预的与 CRS/IPC 无膈肌受累的进行比较。测量了 10 项围手术期结果。根据诊断类型评估总生存率。

结果

术中结果显示手术时间显著增加(7.85 比 7.28,p=0.033)。输血需求无显著差异。术后,III 级和 IV 级并发症增加(36%比 26%,p=0.052)。重症监护停留时间、住院时间、住院死亡和返回手术室没有差异。在呼吸相关并发症方面,气胸(13%比 3%,p=0.001)和胸腔积液(24%比 16%,p=0.043)的发生率增加,而肺炎的差异无统计学意义。总生存率显示,膈肌干预;在结直肠癌中并不影响生存结果(p=0.750,RR=1.077,CI 0.683-1.697),在低级别阑尾黏液性肿瘤中增加相对风险(p=0.025,RR=2.437,CI 1.121-5.298)。

结论

经过我们的三级研究策略,我们得出结论,尽管短期发病率略有增加;膈肌干预不会降低结直肠癌和膈肌疾病在低级别阑尾黏液性肿瘤中的生存率,而膈肌疾病可能是疾病侵袭的独立预后因素。

相似文献

1
Long term survival and perioperative propensity score matched outcomes in diaphragmatic interventions in cytoreductive surgery + intra-peritoneal chemotherapy.在细胞减灭术+腹腔内化疗中的膈膜干预的长期生存和围手术倾向性评分匹配结果。
Eur J Surg Oncol. 2019 Apr;45(4):620-624. doi: 10.1016/j.ejso.2018.12.021. Epub 2018 Dec 29.
2
Long-term Survival and Propensity Score Matched Outcomes of Bilateral Unilateral Diaphragm Interventions in Cytoreductive Surgery plus Intra-peritoneal Chemotherapy.减瘤手术联合腹腔内化疗中双侧与单侧膈肌干预的长期生存及倾向评分匹配结果
Anticancer Res. 2018 Oct;38(10):5917-5921. doi: 10.21873/anticanres.12936.
3
Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.在细胞减灭术+腹腔内化疗中,与剥离相比,膈切除术的长期生存和围手术期倾向评分匹配结果。
Am J Surg. 2020 Apr;219(4):673-680. doi: 10.1016/j.amjsurg.2019.06.018. Epub 2019 Jun 23.
4
Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.术后不良事件对接受减瘤手术联合热腹腔内化疗治疗的阑尾癌伴腹膜转移患者的长期生存无影响。
Ann Surg Oncol. 2016 Dec;23(13):4231-4237. doi: 10.1245/s10434-016-5355-4. Epub 2016 Jun 23.
5
Short- and Long-Term Outcomes of Patients Requiring Gastrectomy During Cytoreductive Surgery and Intraperitoneal Chemotherapy for Lower-Gastrointestinal Malignancies: A Propensity Score-Matched Analysis.行细胞减灭术和腹腔内化疗治疗下消化道恶性肿瘤患者胃切除术的短期和长期结果:倾向评分匹配分析。
Ann Surg Oncol. 2019 Oct;26(11):3627-3635. doi: 10.1245/s10434-019-07510-9. Epub 2019 Jul 10.
6
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Adolescent and Young Adults with Peritoneal Metastases.青少年及年轻成人腹膜转移患者的细胞减灭术及腹腔热灌注化疗
Ann Surg Oncol. 2017 Apr;24(4):875-883. doi: 10.1245/s10434-016-5689-y. Epub 2016 Dec 19.
7
Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.细胞减灭术及腹腔内热灌注化疗对伴有膈肌受累患者的疗效
Ann Surg Oncol. 2015 May;22(5):1639-44. doi: 10.1245/s10434-014-4083-x. Epub 2014 Sep 13.
8
Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.术后并发症可独立预测腹膜恶性肿瘤的癌症相关生存。
Ann Surg Oncol. 2018 Dec;25(13):3950-3959. doi: 10.1245/s10434-018-6823-9. Epub 2018 Oct 9.
9
Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.细胞减灭术和腹腔内热灌注化疗后高级别阑尾或结直肠腹膜癌转移进展的预测因素
Ann Surg Oncol. 2015 May;22(5):1716-21. doi: 10.1245/s10434-014-3985-y. Epub 2014 Aug 22.
10
Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.减瘤手术及围手术期腹腔内化疗的长期生存结果:1225例单机构经验
J Surg Oncol. 2019 Sep;120(4):794-802. doi: 10.1002/jso.25642. Epub 2019 Jul 16.

引用本文的文献

1
Evaluating Respiratory Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Subphrenic Peritonectomy Versus Full Thickness Diaphragm Resection.评估减瘤手术及热灌注化疗联合膈下腹膜切除术与全层膈肌切除术治疗后的呼吸并发症
J Surg Oncol. 2025 Aug;132(2):260-266. doi: 10.1002/jso.70003. Epub 2025 Jun 16.